Remdesivir administration for SARS-CoV-2 pneumonia in ICU and non-ICU patients: outcome and posttreatment differences — the Italian Military Hospital experience

Table 1 Main demographic, hospitalization, and clinical features at the time of hospitalization

Demographic and hospitalization features^a	n (number)	% (percentage)	Clinical features^a		% (percentage)
Age class (years)			Number of comorbidities
24–60	222	49.4	0	143	31.8
61–93	227	51.6	1	87	19.4
			2	56	12.5
Sex			3 or more	163	36.3
Male	339	75.5
Female	110	24.5	Pharmacotherapy
			None	104	23.2
Ward at admission			Remdesivir	262	58.4
UFES	334	74.4	Tocilizumab	6	1.3
ICU	115	25.6	Tocilizumab + remdesivir	4	0.9
			Tocilizumab + Kal	3	0.7
ICU transfer			Kal + ClK	42	9.4
Yes	23	6.9	Kal	15	3.3
No	311	93.1	ClK	13	2.9
IOT (ICU patients)			Outcome
Yes	67	58.3	Survive	354	78.8
No	48	41.7	Death	95	21.2

^aNumbers may not add up to 449 because of missing data. Percentages may not add up to 100 because of rounding

ISSN: 2731-3786